{"id":170544,"date":"2025-08-25T04:19:17","date_gmt":"2025-08-25T08:19:17","guid":{"rendered":"https:\/\/44.250.171.167\/?p=170544"},"modified":"2025-08-25T13:29:58","modified_gmt":"2025-08-25T17:29:58","slug":"akums-q1-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/akums-q1-fy26-earnings-results\/","title":{"rendered":"Akums Q1 FY26 Earnings Results"},"content":{"rendered":"<p>Akums Drugs &amp; Pharmaceuticals Ltd, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. Presenting below its Q1 FY26 Earnings Results.<\/p>\n<h2><strong>Q1 FY26 Earnings Results<\/strong><\/h2>\n<ul>\n<li><strong>Revenue:<\/strong> \u20b91,024 crore, up 0.49% year-on-year (YoY) from \u20b91,019 crore in Q1 FY25.<\/li>\n<li><strong>Total Expenses:<\/strong> \u20b9955 crore, up 1.81% YoY from \u20b9938 crore.<\/li>\n<li><strong>Consolidated Net Profit (PAT):<\/strong> \u20b965 crore, up 6.56% from \u20b961 crore in the same quarter last year.<\/li>\n<li><strong>Earnings Per Share (EPS):<\/strong> \u20b94.03, slightly down 1.23% from \u20b94.08 YoY.<\/li>\n<\/ul>\n<h2><strong>Operational &amp; Strategic Update<\/strong><\/h2>\n<ul>\n<li><strong>Stable Revenue:<\/strong> Revenues remained nearly flat, reflecting steady demand and consistent order flow in the pharmaceutical CDMO segment.<\/li>\n<li><strong>Marginal Expense Growth:<\/strong> Expenses rose marginally by 1.81%, slightly outpacing revenue growth, impacting operating margins.<\/li>\n<li><strong><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/4a247694-4f14-4fde-a31f-24a5236565a1.pdf\" target=\"_blank\" rel=\"noopener\">Moderate Profit Growth<\/a><\/strong><strong>:<\/strong> Net profit increased by over 6%, indicating operational efficiencies and effective cost management.<\/li>\n<li><strong>Market Position:<\/strong> Akums Drugs &amp; Pharmaceuticals continues to strengthen its position as a trusted CDMO partner with diversified product offerings.<\/li>\n<li><strong>Strategic Focus:<\/strong> The company emphasizes capacity expansion, quality enhancement, and client diversification to support sustainable growth.<\/li>\n<\/ul>\n<h2><strong>Corporate Developments in Q1 FY26 Earnings<\/strong><\/h2>\n<p><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/4a247694-4f14-4fde-a31f-24a5236565a1.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> results underscore moderate profit improvement amid stable revenue, enabled by focused expense control and operational resilience.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-170545\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png\" alt=\"AKUMS Q1 FY26 Earnings Results\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n<h2><strong>Looking Ahead<\/strong><\/h2>\n<p>Akums Drugs &amp; Pharmaceuticals Ltd plans to capitalize on capacity additions, new client wins, and enhanced service capabilities. The goal is sustained growth and improved profitability through FY26 and beyond.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts,<a href=\"https:\/\/44.250.171.167\/symbol\/akums\/\"> click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Akums Drugs &amp; Pharmaceuticals Ltd, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b91,024 crore, up 0.49% year-on-year (YoY) from \u20b91,019 crore in Q1 FY25. Total Expenses: \u20b9955 crore, up [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":170545,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[1115],"class_list":["post-170544","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":172881,"url":"https:\/\/alphastreet.com\/india\/akums-drugs-q2-fy26-earnings-results\/","url_meta":{"origin":170544,"position":0},"title":"Akums Drugs Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"December 3, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004 as India's leading pharmaceutical CDMO offering comprehensive product development and manufacturing services across formulations, reported lower profitability for Q2FY26. Financial Highlights: Revenues declined 1.45% year-on-year to \u20b91,018 crore from \u20b91,033 crore, with CDMO up 0.7% to \u20b9804 crore but API\/international formulations down.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":180863,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-akums-drugs-pharmaceuticals-reports-14-8-revenue-growth-in-q3-fy26-results\/","url_meta":{"origin":170544,"position":1},"title":"Earnings Summary &#8211; Akums Drugs &amp; Pharmaceuticals Reports 14.8% Revenue Growth in Q3 FY26 Results","author":"Staff Correspondent","date":"February 15, 2026","format":false,"excerpt":"Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS), a pharmaceutical contract development and manufacturing organization (CDMO) announced its third-quarter and nine-month financial results for fiscal year 2026 on February 13, 2026. On the day results were released, the stock closed at \u20b9484.95, representing a one-day gain of \u20b933.60 or 7.44%. Quarterly\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":169930,"url":"https:\/\/alphastreet.com\/india\/alembic-pharmaceuticals-q1-fy26-earnings-results-revenue-up-10-net-profit-rises-14-yoy\/","url_meta":{"origin":170544,"position":2},"title":"Alembic Pharmaceuticals Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 8, 2025","format":false,"excerpt":"Alembic Pharmaceuticals Limited is a leading player in the pharmaceutical industry, engaged in the development, manufacturing, and marketing of formulations and active pharmaceutical ingredients (APIs). The company operates 3 R&D centers and 5 advanced manufacturing facilities, supporting global exports and a robust domestic presence. Presenting below are its Q1 FY26\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"APLLTD Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170458,"url":"https:\/\/alphastreet.com\/india\/aarti-pharmalabs-q1-fy26-earnings-results\/","url_meta":{"origin":170544,"position":3},"title":"Aarti Pharmalabs Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 21, 2025","format":false,"excerpt":"Aarti Pharmalabs Ltd, incorporated in 2019, is a manufacturer of pharmaceuticals and nutraceuticals. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9386 crore, down 30.45% year-on-year (YoY) from \u20b9555 crore in Q1 FY25. Total Expenses: \u20b9323 crore, down 33.26% YoY from \u20b9484 crore. Consolidated Net\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AARTIPAHRM Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168657,"url":"https:\/\/alphastreet.com\/india\/akums-drugs-12-rise-in-revenue\/","url_meta":{"origin":170544,"position":4},"title":"Akums Drugs &#038; Pharmaceuticals Ltd Q4FY25; 12% rise in Revenue","author":"Divyansh_Kasana","date":"June 5, 2025","format":false,"excerpt":"Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services. Financial Results: Akums Drugs & Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b91,056.00 Crores up from \u20b9944.00 Crore year on year, a rise of\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169505,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q1-fy26-earnings-results-a-whopping-1146-rise-in-profits\/","url_meta":{"origin":170544,"position":5},"title":"Laurus Labs Ltd Q1 FY26 Earnings Results &#8211; A whopping 1146% rise in Profits","author":"Chirag Gupta","date":"July 29, 2025","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=170544"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170544\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/170545"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=170544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=170544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=170544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}